PFIZER INC.

Stuart Therapeutics appoints Tracy Valorie and Jason Werner to its Board of Directors, expanding to five members. They replace Robert O. Baratta and Diane Black, enhancing ophthalmology therapeutics expertise.

Sam Isaly, manager of Finsbury Worldwide Pharmaceutical, is cautious about biotechnology stocks' short-term prospects, despite their profit potential. He emphasizes maintaining exposure due to compelling investment opportunities, with accelerating drug discovery. The trust invests 20-40% in smaller-cap biotech and 60-80% in larger-cap pharma, more optimistic about the latter. Top holdings include Pfizer, Sanofi-Synthelabo, Novartis, Altana, and Orchid BioSciences. The trust's NAV rose 47.2% in six months, outperforming its benchmark.

Recursion Pharmaceuticals, an AI-powered biotech, leverages AI for drug discovery, potentially revolutionizing medicine. Its merger with Exscientia enhances its platform, offering a promising pipeline of therapeutic candidates. However, financial losses and competitive landscape pose risks, making it too early to invest with conviction.

Novo Holdings completes $16.5B Catalent Pharma Solutions buyout. Merck pays $112M upfront for obesity pill. Ottimo Pharma raises $140M for cancer therapy. Novo Nordisk invests $1.2B in Denmark factory. Angitia Biopharmaceuticals raises $120M for musculoskeletal candidates. Novartis closes MorphoSys sites, laying off 330. SiteOne Therapeutics secures $100M for non-opioid pain drugs. Novo Nordisk's obesity drug underperforms. Bristol Myers Squibb invests $100M in BioArctic's Alzheimer antibodies. Sudan's healthcare collapses. Tonix Pharmaceuticals files NDA for fibromyalgia drug. Neurocrine Biosciences wins FDA approval for Crenessity. Edgewise Therapeutics discusses accelerated approval for Becker muscular dystrophy. FDA places partial hold on PepGen's Duchenne therapy. Checkpoint Therapeutics' immunotherapy approved. WHO opens Academy in Lyon. GSK's Jemperli earns FDA Breakthrough status. Sanofi's duvakitug shows remission in ulcerative colitis. Sandoz agrees to $275M settlement over drug pricing. Pfizer projects 2025 earnings. Mesoblast's Ryoncil approved as 1st MSC therapy for graft-vs-host disease.

FDA approves Pfizer's BRAFTOVI (encorafenib) with cetuximab and mFOLFOX6 for metastatic colorectal cancer (mCRC) with BRAF V600E mutation. Based on BREAKWATER trial, the combination showed significant improvement in response rate and durability. This is the first BRAF-targeted therapy regimen for first-line treatment of BRAF V600E-mutant mCRC.

Pfizer's BRAFTOVI® (encorafenib) in combo with cetuximab and mFOLFOX6 approved by FDA for first-line treatment of metastatic colorectal cancer with BRAF V600E mutation, based on 61% overall response rate in Phase 3 BREAKWATER trial.

The global targeted protein degradation market is projected to grow from USD 0.548 billion in 2023 to USD 4.37 billion by 2034, driven by precision medicine, drug discovery investments, and technological advancements. PROTACs lead the market, with molecular glues expected to grow fastest. Therapy development dominates applications, particularly in cancer and neurodegenerative diseases. Pharmaceutical & biotechnology companies are the largest end-users. North America leads in revenue, while Asia-Pacific shows the highest growth rate.

The 'Meningitis - Global Clinical Trials Review, 2024' report by ResearchAndMarkets.com offers an overview of meningitis clinical trials, including trial numbers, enrollment, regions, countries, phases, statuses, and sponsor types. It highlights prominent drugs and companies involved, providing insights into global clinical trials landscape and enrollment trends.

Applied Therapeutics announces leadership changes: John H. Johnson named Executive Chairman, Shoshana Shendelman steps down as CEO, and Les Funtleyder appointed Interim CEO. Business updates include evaluating response to FDA Complete Response Letter for govorestat, withdrawal of MAA to EMA, and ongoing SORD Deficiency clinical program. Inducement awards approved for Johnson.

The Pediatric Clinical Trials Market is projected to grow from US$ 20.1 Billion in 2023 to US$ 33.0 Billion by 2033, with a CAGR of 5.0%. North America led in 2023 with a 39.10% share. Challenges include ethical concerns, limited recruitment, and high costs. Innovations like adaptive trials and digital technologies are enhancing efficiency.